MARKET

PYXS

PYXS

Pyxis Oncology, Inc.
NASDAQ
3.190
+0.330
+11.54%
Opening 10:19 06/30 EDT
OPEN
2.490
PREV CLOSE
2.860
HIGH
3.400
LOW
2.440
VOLUME
5.07M
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
0.9700
MARKET CAP
202.10M
P/E (TTM)
-2.4499
1D
5D
1M
3M
1Y
5Y
1D
Pyxis Oncology posts corporate deck outlining strategy to build differentiated antibody-drug conjugate company around MICVO program in head and neck cancer
PUBT · 5h ago
Pyxis Oncology announces up to $114M private placement
TipRanks · 5h ago
Guggenheim Sticks to Its Buy Rating for Pyxis Oncology (PYXS)
TipRanks · 5h ago
Pyxis Oncology Commences ~$50M Offering Of 19.6M Common Shares At $2.551/Share
Benzinga · 5h ago
Pyxis Oncology prices USD 50 million private placement at USD 2.55 a share
PUBT · 5h ago
PYXIS ONCOLOGY - EXPECTS UPDATED PHASE 1 MONOTHERAPY DATA IN FALL 2026 AND PHASE 1/2 DATA IN Q4 2026
Reuters · 5h ago
PYXIS ONCOLOGY - UPFRONT PROCEEDS EXPECTED TO EXTEND CASH RUNWAY INTO Q2 2027
Reuters · 5h ago
PYXIS ONCOLOGY: FINANCING LED BY BVF PARTNERS L.P. WITH PARTICIPATION FROM GORDONMD GLOBAL INVESTMENTS, RTW INVESTMENTS, & COASTLANDS CAPITAL
Reuters · 5h ago
More
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Webull offers Pyxis Oncology Inc stock information, including NASDAQ: PYXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PYXS stock methods without spending real money on the virtual paper trading platform.